, We also thank Franck Morschhauser from the Centre Hospitalier Régional Universitaire de Lille in Lille, France, for his contributions
, Chrysalis Medical Communications
Advisory board member and/or consultant for ,
, Partner Therapeutics, and TeneoBio; research funding from Bristol-Myers Squibb, Kite/Gilead, Merck, and Spectrum Pharmaceuticals
, Personal fees from AbbVie and Roche
, Advisory board member and/or consultant for
, Consultant for Bristol-Myers Squibb
Advisory board member and/or consultant for Kite ,
, Cell Medica
,
, Advisory board member and/or consultant for Prometheus; research funding from Abbott
Advisory board member for Seattle Genetics and Janssen Scientific; personal fees from Verastem ,
Advisory board member for AstraZeneca; research funding from Bristol-Myers Squibb ,
Advisory board member/symposia participant for ,
,
Consultant for Kite, Novartis, Celgene, Humanigen, Pfizer, and Precision BioSciences ,
Personal fees from Takeda; non-financial support from Takeda ,
,
Former employee of Bristol-Myers Squibb ,
Employee and stock owner of Bristol-Myers Squibb ,
Employee and stock owner of Bristol-Myers Squibb ,
, Research funding from Bristol-Myers Squibb, Shimadzu Corporation, and Tesaro
Dragonfly, Innate Pharma, Abpro, Apexigen, Nohla, Spotlight, Forty Seven Inc, xCella, Immunocore, and Walking Fish; research funding from Pfizer, Bristol-Myers Squibb, and Pharmacyclics. REFERENCES 1. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 1. 2019. National Comprehensive Cancer Network, Scientific advisory board for Five Prime ,
Diffuse large B-cell lymphoma-treatment approaches in the molecular era, Nat Rev Clin Oncol, vol.11, issue.1, pp.12-23, 2014. ,
Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, Future Sci OA, vol.4, issue.7, p.322, 2018. ,
Non-Hodgkin lymphoma, Lancet, vol.390, pp.298-310, 2017. ,
Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges, J Comp Eff Res, vol.3, issue.1, pp.95-107, 2014. ,
Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study, J Clin Oncol, vol.33, issue.23, pp.2516-2522, 2015. ,
update on diagnosis and management, Am J Hematol, vol.93, issue.2, pp.296-305, 2018. ,
, Opdivo (nivolumab)
, Bristol-Myers Squibb Company, 2019.
, Keytruda (pembrolizumab)
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma, Clin Cancer Res, vol.15, issue.20, pp.6446-6453, 2009. ,
Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study, J Clin Oncol, vol.37, issue.6, pp.481-489, 2019. ,
PD-1 blockade with pembrolizumab in relapsed low grade non-Hodgkin lymphoma, Blood, vol.130, p.4055, 2017. ,
Targeting costimulatory molecules to improve antitumor immunity, J Biomed Biotechnol, p.926321, 2012. ,
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies, Blood, vol.131, issue.1, pp.49-57, 2018. ,
Boosting cancer immunotherapy with anti-CD137 antibody therapy, Clin Cancer Res, vol.21, issue.14, pp.3113-3120, 2015. ,
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody, Clin Cancer Res, vol.23, issue.8, pp.1929-1936, 2017. ,
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes, Cancer Res, vol.71, issue.3, pp.801-811, 2011. ,
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy, BMB Rep, vol.47, issue.3, pp.122-129, 2014. ,
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion, Blood, vol.114, issue.16, pp.3431-3438, 2009. ,
Assessing the potential for enhanced antibody-dependent cell-mediated cytotoxicity by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors, J Immunother Cancer, vol.4, issue.1, p.267, 2016. ,
Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies, J Immunother Cancer, vol.4, issue.1, p.7, 2016. ,
, , 2020.
Revised response criteria for malignant lymphoma, J Clin Oncol, vol.25, issue.5, pp.579-586, 2007. ,
S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity, Oncoimmunology, vol.7, issue.4, p.1296996, 2018. ,
Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway, Clin Cancer Res, vol.24, issue.5, pp.1138-1151, 2018. ,
,
, , 2019.
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study, Blood, vol.92, issue.6, pp.1927-1932, 1998. ,
A phase I study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with rituximab in patients with CD20+ non-Hodgkin?s lymphoma, Hematol Oncol, vol.35, issue.2, p.267, 2017. ,
An update on anti-CD137 antibodies in immunotherapies for cancer, Int J Mol Sci, vol.20, issue.8, p.1822, 2019. ,
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity, Nat Commun, vol.9, issue.1, p.4809, 2018. ,
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity, Nat Commun, vol.10, issue.1, p.2141, 2019. ,
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy, Sci Transl Med, vol.11, issue.496, p.5989, 2019. ,